HHS Develops Guidance to Reduce SSRI Antidepressant Prescribing
The Department of Health and Human Services is working with mental health professionals to develop guidance aimed at reducing the use of selective serotonin reuptake inhibitor (SSRI) antidepressants. HHS officials convened a private meeting to advance this effort. The timing and scope of any formal guidance release remain unclear. For Medicaid managed care organizations, this could signal future prior authorization requirements, utilization management changes, or quality measure adjustments affecting behavioral health pharmacy benefits and member care protocols.
Federal guidance discouraging SSRI use would require MCOs to redesign behavioral health pharmacy strategies, potentially affecting prior authorization protocols, provider education, and quality metrics for depression treatment.
Behavioral Health · Pharmacy · Managed Care
You might also like